How frequently should a patient taking amiodarone be screened for thyroid dysfunction?

Brazilian Journal of Medical and Biological Research

Volumn 42, Issue 8, 2009, Pages 744-749

  Pazin Filho, A ^a   de Jesus, A M X ^a   Magalhaes P K R ^a   Melato, L H ^a   Campos, D ^a   Maciel, B C ^a   Maciel, L M Z ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amiodarone; Antiarrhythmic drug; Chagas' disease; Thyroid dysfunction

Indexed keywords

AMIODARONE; IODINE;

ADOLESCENT; ARTICLE; CHAGAS DISEASE; CHILD; CONTROLLED STUDY; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREVALENCE; PROGNOSIS; SCREENING TEST; THYROID DISEASE; THYROID FUNCTION TEST; TREATMENT DURATION;

EID: 70349505724     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2009000800009     Document Type: Article

References (15)

1. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999; 100: 2025-2034.
2. Kinsara AJ. Amiodarone in the new ACLS guidelines. Circulation 2001; 104: E44.
3. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30: 791-798.
4. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005; 118: 706-714.
5. Martino E, Aghini-Lombardi F, Bartalena L, Grasso L, Loviselli A, Velluzzi F, et al. Enhanced susceptibility to amiodarone-induced hypothyroidism in patients with thyroid autoimmune disease. Arch Intern Med 1994; 154: 2722-2726.
6. Gheri RG, Pucci P, Falsetti C, Luisi ML, Cerisano GP, Gheri CF, et al. Clinical, biochemical and therapeutical aspects of amiodarone-induced hypothyroidism (AIH) in geriatric patients with cardiac arrhythmias. Arch Gerontol Geriatr 2004; 38: 27-36.
7. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160: 1741-1748.
8. Stelfox HT, Ahmed SB, Fiskio J, Bates DW. Monitoring amiodarone's toxicities: recommendations, evidence, and clinical practice. Clin Pharmacol Ther 2004; 75: 110-122.
9. Ladenson PW, Singer PA, Ain KB, Bagchi N, Bigos ST, Levy EG, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 2000; 160: 1573-1575.
10. Stata Statistical Software. [Computer program]. College Station: StataCorp.; 2005.
11. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991; 91: 507-511.
12. Schaan BD, Cunha CP, Francisconi A, Zottis B, Brum G, Bruch RS, et al. Amiodarone-induced thyroid dysfunction in a tertiary center in south Brazil. Arq Bras Endocrinol Metabol 2005; 49: 916-922.
13. Bartalena L, Wiersinga WM, Tanda ML, Bogazzi F, Piantanida E, Lai A, et al. Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clin Endocrinol 2004; 61: 494-502.
14. Silva JR, Guariento ME, Fernandes GA, Maciel RM, Ward LS. Impact of long-term administration of amiodarone on the thyroid function of patients with Chagas' disease. Thyroid 2004; 14: 371-377.
15. Maciel LMZ. O exame físico da tireóide. Medicina 2007; 40: 72-77.